Volume 12, Issue 6 (8-2014)                   IJRM 2014, 12(6): 427-0 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aflatoonian A, Davar R, Hojjat F. Elevated serum progesterone/ MII oocyte ratio on the day of human chorionic gonadotropin administration can predict impaired endometrial receptivity. IJRM 2014; 12 (6) :427-0
URL: http://ijrm.ir/article-1-546-en.html
1- Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2- Department of Obstetrics and Gynecology, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran , farzanehhojjat@gmail.com
Abstract:   (3177 Views)
Background: Increased serum progesterone on the day of human chorionic gonadotropin administration may affect in vitro fertilization (IVF) outcome. Objective: The aim of this study was to evaluate whether progesterone elevation on the day of human chorionic gonadotropin administration is associated with the IVF outcome. Materials and Methods: To determine the relationship between serum progesterone on the day of HCG and the outcome of IVF-embryo transfer treatment, 378 infertile patients undergoing IVF-embryo transfer at Yazd Research and Clinical Center for Infertility from October 2009 to March 2011 were prospectively studied. Results: In this study, absolute p-value and P/ER2R ratio were not a good predictor outcome of in-vitro fertilization but progesterone per metaphase II were predictive of implantation rate and pregnancy rate with statistically significant results but had no effect on the fertilization rate. Conclusion: We suggest avoided the increased progesterone that the cause of advanced endometrial maturation and impaired endometrial receptivity. If the progesterone is greater than 0.32 per oocyte metaphase II, the embryo transfer can be canceled and freezing all embryos for future transfer must be considered, to increase acceptance of the endometrium and thus increase the success rate.
Full-Text [PDF 195 kb]   (643 Downloads) |   |   Full-Text (HTML)  (403 Views)  
Type of Study: Original Article |

References
1. Fleming R, Jenkins J. The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reprod Biomed Online 2010; 21: 446-449. [DOI:10.1016/j.rbmo.2010.05.018]
2. Ubaldi F, Camus M, Smitz J, Bennink HC, Steirteghem AV, Devroey P. Premature luteinization in in-vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH. Fertil Steril 1996; 66: 275-280. [DOI:10.1016/S0015-0282(16)58453-2]
3. Fleming R. Progesterone elevation on the day of hCG: methodological issues. Hum Reprod Update 2008; 14: 391-392. [DOI:10.1093/humupd/dmn019]
4. Moon YS, Tsang BK, Simpson C, Armstrong DT. 17 beta-Estradiol biosynthesis in cultured granulosa and thecal cells of human ovarian follicles: stimulation by follicle-stimulating hormone. J Clin Endocrinol Metab 1978; 47: 263-267. [DOI:10.1210/jcem-47-2-263]
5. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006; 21: 3217-3227. [DOI:10.1093/humrep/del284]
6. Ertunc D, Tok EC, Savas A, Ozturk I, Dilek S. Gonadotropin-releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome. Fertil Steril 2010; 93: 1179-1184. [DOI:10.1016/j.fertnstert.2008.11.030]
7. Stadtmauer LA, Sarhan A, Duran EH, Beydoun H, Bocca S, Pultz B, et al. The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2011; 95: 216-220. [DOI:10.1016/j.fertnstert.2010.05.023]
8. Prapas N, Tavaniotou A, Panagiotidis Y, Prapa S, Kasapi E, Goudakou M, et al. GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial. Reprod Biomed Online 2009; 18: 276-281. [DOI:10.1016/S1472-6483(10)60266-0]
9. Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertil Steril 2008; 89: 1234-1239. [DOI:10.1016/j.fertnstert.2007.04.060]
10. Steward RG, Gill I, Williams DB, Witz CA, Griffith J, Haddad GF. Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial. Fertil Steril 2011; 95: 434-436. [DOI:10.1016/j.fertnstert.2010.07.1076]
11. Elnashar A. Progesterone rise on the day of HCG administration (premature luteinization) in IVF: An overdue update. J Assist Reprod Genet 2010; 27: 149-155. [DOI:10.1007/s10815-010-9393-8]
12. Antoine JM, Firmin C, Salat-Baroux J, Alvarez S, Cornet D, Mandelbaum J, et al. [Prognostic value of preovulatory elevations of plasma progesterone during in vitro fertilization using LHRH agonists in a long protocol]. J Gynecol Obstet Biol Reprod (Paris) 1992; 21: 629-634.
13. Levy MJ, Smotrich DB, Widra EA, Sagoskin AW, Murray DL, Hall JL. The predictive value of serum progesterone and 17-OH progesterone levels on in-vitro fertilization outcome. J Assist Reprod Genet 1995; 12: 161-166. [DOI:10.1007/BF02211792]
14. Hofmann GE, Khoury J, Michener C. Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in-vitro fertilization is not associated with diminished ovarian reserve. Fertil Steril 2002; 78: 47-50. [DOI:10.1016/S0015-0282(02)03162-X]
15. Seow KM, Lin YH, Huang LW, Hsieh BC, Huang SC, Chen CY, et al. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in-vitro fertilization or intracytoplasmic sperm injection cycles. Gynecol Endocrinol 2007; 23: 338-342. [DOI:10.1080/09513590701403629]
16. Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in-vitro fertilization? A systematic review and meta-analysis. Hum Reprod Update 2007; 13: 343-355. [DOI:10.1093/humupd/dmm007]
17. Nikolettos N, Asimakopoulos B, Koster F, Schopper B, Schulz C, Caglar GS, et al. Cytokine profile in cases with premature elevation of progesterone serum concentrations during ovarian stimulation. Physiol Res 2008; 57: 215-224.
18. Saleh HA, Omran MS, Draz M. Does subtle progesterone rise on the day of HCG affect pregnancy rate in long agonist ICSI cycles? J Assist Reprod Genet 2009; 26: 239-242. [DOI:10.1007/s10815-009-9309-7]
19. Segal S, Glatstein I, McShane P, Hotamisligil S, Ezcurra D, Carson R. Premature luteinization and in-vitro fertilization outcome in gonadotropin/ gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome. Fertil Steril 2009; 91: 1755-1759. [DOI:10.1016/j.fertnstert.2008.02.009]
20. Sönmezer M, Pelin Cil A, Atabekoglu C, Özkavukçu S, Özmen B. Does premature luteinization or early surge of LH impair cycle outcome? Report of two successful outcomes. J Assist Reprod Genet 2009; 26: 159-163. [DOI:10.1007/s10815-009-9299-5]
21. Garcia JE, Acosta AA, Hsiu JG, Jones HW Jr. Advanced endometrial maturation after ovulation induction with human menopausal gonadotropin/ human chorionic gonadotropin for in vitro fertilization. Fertil Steril 1984; 41: 31-35. [DOI:10.1016/S0015-0282(16)47536-9]
22. Silverberg KM, Burns WN, Olive DL, Riehl RM, Schenken RS. Serum progesterone levels predict success of in-vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. J Clin Endocrinol Metab 1991; 73: 797-803. [DOI:10.1210/jcem-73-4-797]
23. Fanchin R, de Ziegler D, Taieb J, Hazout A, Frydman R. Premature elevation of plasma progesterone alters pregnancy rates of in-vitro fertilization and embryo transfer. Fertil Steril 1993; 59: 1090-1094. [DOI:10.1016/S0015-0282(16)55933-0]
24. Burns WN, Witz CA, Klein NA, Silverberg KM, Schenken RS. Serum progesterone concentrations on the day after human chorionic gonadotropin administration and progesterone/oocyte ratios predict in-vitro fertilization/embryo transfer outcome. J Assist Reprod Genet 1994; 11: 17-23. [DOI:10.1007/BF02213692]
25. Sims JA, Seltman HJ, Muasher SJ. Early follicular rise of serum progesterone concentration in response to a flare-up effect of gonadotrophin-releasing hormone agonist impairs follicular recruitment for in-vitro fertilization. Hum Reprod 1994; 9: 235-240. [DOI:10.1093/oxfordjournals.humrep.a138488]
26. Harada T, Yoshida S, Katagiri C, Takao N, Ikenari T, Toda T, et al. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin. Hum Reprod 1995; 10: 1060-1064. [DOI:10.1093/oxfordjournals.humrep.a136094]
27. Tavaniotou A, Bourgain C, Albano C, Platteau P, Smitz J, Devroey P. Endometrial integrin expression in the early luteal phase in natural and stimulated cycles for in-vitro fertilization. Eur J Obstet Gynecol Reprod Biol 2003; 108: 67-71. [DOI:10.1016/S0301-2115(02)00428-1]
28. Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update 2003; 9: 515-522. [DOI:10.1093/humupd/dmg045]
29. Ozcakir HT, Levi R, Tavmergen E, Goker EN. Premature luteinization defined as progesterone estradiol ratio >1 on hCG administration day seems to adversely affect clinical outcome in long gonadotropin-releasing hormone agonist cycles. J Obstet Gynaecol Res 2004; 30: 100-104. [DOI:10.1111/j.1447-0756.2003.00166.x]
30. Azem F, Tal G, Lessing JB, Malcov M, Ben-Yosef D, Almog B, et al. Does high serum progesterone level on the day of human chorionic gonadotropin administration affect pregnancy rate after intracytoplasmic sperm injection and embryo transfer? Gynecol Endocrinol 2008; 24: 368-372. [DOI:10.1080/09513590802196353]
31. Lai TH, Lee FK, Lin TK, Horng SG, Chen SC, Chen YH, et al. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin releasing hormone agonist protocol. Fertil Steril 2009; 92: 508-514. [DOI:10.1016/j.fertnstert.2008.06.036]
32. Lee FK, Lai TH, Lin TK, Horng SG, Chen SC. Relationship of progesterone/estradiol ratio on day of hCG administration and pregnancy outcomes in high responders undergoing in-vitro fertilization. Fertil Steril 2009; 92: 1284-1289. [DOI:10.1016/j.fertnstert.2008.08.024]
33. Polotsky AJ, Daif JL, Jindal S, Lieman HJ, Santoro N, Pal L. Serum progesterone on the day of human chorionic gonadotropin administration predicts clinical pregnancy of sibling frozen embryos. Fertil Steril 2009; 92: 1880-1885. [DOI:10.1016/j.fertnstert.2008.09.017]
34. Kilicdag EB, Haydardedeoglu B, Cok T, Hacivelioglu SO, Bagis T. Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles. Arch Gynecol Obstet 2010; 281: 747-752. [DOI:10.1007/s00404-009-1248-0]
35. Lai TH, Lin TK, Lee FK. Reply of the Authors: Premature luteinization defined by an increased progesterone/ estradiol ratio on day of human chorionic gonadotropin administration is a manifestation of diminished ovarian responsiveness to controlled ovarian hyperstimulation. Fertil Steril 2010; 93: e30. [DOI:10.1016/j.fertnstert.2010.01.001]
36. Younis JS, Ben-Shlomo I, Ben-Ami M. Premature luteinization defined by an increased progesterone/ estradiol ratio on day of human chorionic gonadotropin administration is a manifestation of diminished ovarian responsiveness to controlled ovarian hyperstimulation. Fertil Steril 2010; 93: e29. [DOI:10.1016/j.fertnstert.2010.01.002]
37. Bosch E. Reply: Elevated P level on the day of hCG administration is related to FSH dose: is it the whole truth? Hum Reprod 2011; 26: 499-500. [DOI:10.1093/humrep/deq356]
38. Cakmak H, Taylor HS. Implantation failure: molecular mechanisms and clinical treatment. Hum Reprod Update 2011; 17: 242-253. [DOI:10.1093/humupd/dmq037]
39. Elgindy EA. Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy. Fertil Steril 2011; 95: 1639-1644. [DOI:10.1016/j.fertnstert.2010.12.065]
40. Labarta E, Martínez-Conejero JA, Alamá P, Horcajadas JA, Pellicer A, Simón C, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod 2011; 26: 1813-1825. [DOI:10.1093/humrep/der126]
41. Li R, Qiao J, Wang L, Li L, Zhen X, Liu P, et al. MicroRNA array and microarray evaluation of endometrial receptivity in patients with high serum progesterone levels on the day of hCG administration. Reprod Biol Endocrinol 2011; 9: 29. [DOI:10.1186/1477-7827-9-29]
42. Van Vaerenbergh I, Fatemi HM, Blockeel C, Van Lommel L, In't Veld P, Schuit F, et al. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online 2011; 22: 263-271. [DOI:10.1016/j.rbmo.2010.11.002]
43. Papanikolaou EG, Kolibianakis EM, Pozzobon C, Tank P, Tournaye H, Bourgain C, et al. Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertil Steril 2009; 91: 949-952. [DOI:10.1016/j.fertnstert.2006.12.064]
44. Younis JS, Matilsky M, Radin O, Ben-Ami M. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in-vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist. Fertil Steril 2001; 76: 294-299. [DOI:10.1016/S0015-0282(01)01918-5]
45. Ou YC, Lan KC, Chang SY, Kung FT, Huang FJ. Increased Progesterone/Estradiol Ratio on the Day of hCG Administration Adversely Affects Success of In-Vitro Fertilization-Embryo Transfer in Patients Stimulated with Gonadotropin-releasing Hormone Agonist and Recombinant Follicle-stimulating Hormone. Taiwan J Obstet Gynecol 2008; 47: 168-174. [DOI:10.1016/S1028-4559(08)60075-3]
46. Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 2005; 84: 394-401. [DOI:10.1016/j.fertnstert.2005.02.036]
47. Huddleston HG, Jackson KV, Doyle JO, Racowsky C. hMG increases the yield of mature oocytes and excellent-quality embryos in patients with a previous cycle having a high incidence of oocyte immaturity. Fertil Steril 2009; 92: 946-949. [DOI:10.1016/j.fertnstert.2009.02.039]
48. Lockwood GM, Pinkerton SM, Barlow DH. Endocrinology: A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles. Hum Reprod 1995; 10: 293-298. [DOI:10.1093/oxfordjournals.humrep.a135930]
49. Bakas P, Konidaris S, Liapis A, Gregoriou O, Tzanakaki D, Creatsas G. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril 2011; 95: 2024-2028. [DOI:10.1016/j.fertnstert.2011.01.167]
50. Lainas T, Zorzovilis J, Petsas G, Stavropoulou G, Cazlaris H, Daskalaki V, et al. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Hum Reprod 2005; 20: 2426-2433. [DOI:10.1093/humrep/dei106]
51. Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL, et al. Delayed endometria maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol 1992; 167: 60-65. [DOI:10.1016/S0002-9378(11)91627-5]
52. Escudero EL, Boerrigter PJ, Bennink HJ, Epifanio R, Horcajadas JA, Olivennes F, et al. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in-vitro fertilization. J Clin Endocrinol Metab 2005; 90: 2081-2088. [DOI:10.1210/jc.2004-1160]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb